Opportunities and Challenges Ahead While the telehealthGLP-1 convergence promises efficiency and scalability, it comes with challenges that healthcare leaders must address: Affordability & Equity: GLP-1 drugs remain costly, raising concerns about disparities in access
Because lean populations sit outside the studied population
GLP-1 mania fuels 63 percent surge in Novo's 2024 revenue, while Lillys Mounjaro stalls pre-launch Novo Nordisk didnt just pass 300 billion won ($207 million) in Korea last yearit tore through the milestone at full sprint, raking in 374.6 billion ($259 million) won on the back of a GLP-1 craze that cleared shelves, lit up clinics and left rival Eli Lilly trailing far behind
As with all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team
Book your consultation today and experience the Sculptures difference
This layered approach helps patients know what to take daily, what to use during a flare, and when symptoms require stronger intervention